Elmira T. Flem

Skoyen, 0213, Norway

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications

Economic Evaluation of PCV21 Use in Populations with Increasing Serotype 4 Invasive Pneumococcal Disease in the US: An Attributable Fraction Threshold Analysis.

Economic Evaluation of PCV21 Use in Populations with Increasing Serotype 4 Invasive Pneumococcal Disease in the US: An Attributable Fraction Threshold Analysis.

Journal: Infectious diseases and therapy
Published: February 10, 2026

Health disparities in the burden of pneumococcal disease in US adults.

Health disparities in the burden of pneumococcal disease in US adults.

Journal: Pneumonia (Nathan Qld.)
Published: February 10, 2025

Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States.

Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States.

Journal: Expert review of vaccines
Published: December 16, 2024

Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review.

Indirect protection in adults ≥18 years of age from pediatric pneumococcal vaccination: a review.

Journal: Expert review of vaccines
Published: October 22, 2024

Preferences and attitudes of healthcare providers towards pneumococcal vaccines for adults in the United States.

Preferences and attitudes of healthcare providers towards pneumococcal vaccines for adults in the United States.

Journal: Expert review of vaccines
Published: October 19, 2024

Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 - December 2019.

Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 - December 2019.

Journal: Vaccine
Published: November 21, 2023

No association between disease severity and respiratory syncytial virus subtypes RSV-A and RSV-B in hospitalized young children in Norway.

No association between disease severity and respiratory syncytial virus subtypes RSV-A and RSV-B in hospitalized young children in Norway.

Journal: PloS one
Published: August 16, 2023

Corrigendum to 'The burden of respiratory syncytial virus in children under 5 years of age in Norway' [Journal of Infection Volume 84, Issue 2 (2022) Pages 205-215].

Corrigendum to 'The burden of respiratory syncytial virus in children under 5 years of age in Norway' [Journal of Infection Volume 84, Issue 2 (2022) Pages 205-215].

Journal: The Journal of infection
Published: December 26, 2022

Risk factors associated with severe disease in respiratory syncytial virus infected children under 5 years of age.

Risk factors associated with severe disease in respiratory syncytial virus infected children under 5 years of age.

Journal: Frontiers in pediatrics
Published: July 27, 2022

The burden of hospital-attended influenza in Norwegian children.

The burden of hospital-attended influenza in Norwegian children.

Journal: Frontiers in pediatrics
Published: June 07, 2022

The burden of respiratory syncytial virus in children under 5 years of age in Norway.

The burden of respiratory syncytial virus in children under 5 years of age in Norway.

Journal: The Journal of infection
Published: November 07, 2021

Cost and health impact analysis of herpes zoster vaccination in Norway.

Cost and health impact analysis of herpes zoster vaccination in Norway.

Journal: Expert review of pharmacoeconomics & outcomes research
Published: September 07, 2021
Showing 1-12 of 44

Last Updated: 09/26/2026